| Acute and Chronic Complications
Acute and Chronic Complications

DasiglucagonHypopal Autoinjector as a Fast and Effective Treatment for Severe Hypoglycemia: Results of a Phase 3 Trial

book_2 Source: ADA 2020 - Poster session
calendar_today Published on Medfyle: July 2020
headphones 3 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • Glucagon is a critical rescue medication to treat severe hypoglycemia in people with insulin treated diabetes
  • Glucagon is under-prescribed & under-utilized. Glucagon injection kits require user training and multiple preparation steps. These are barriers to their prescription and effective utilization, especially under emergent circumstances.
  • Dasiglucagon is a specific glucagon receptor agonist with a 7 amino acid substitutions to native glucagon which enables it to be physically and chemically stable in aqueous solution. 
  • This study showed that Dasiglucagon is a fast and effective treatment for severe hypoglycemia. Dasiglucagon in an autoinjector form and dasiglucagon used in dual hormone closed loop systems have the potential to benefit people with insulin-treated diabetes.
Presenting Author
Read more arrow_downward Hide arrow_upward

Timothy S Bailey, MD, FACE
President & CEO, AMCR Institute (Escondido, CA)
Clinical Associate Professor, Department of Medicine, UC San Diego School of Medicine


Dr. Bailey is the CEO and President of the AMCR Institute in Escondido, California and a clinical associate professor of medicine at the University of California at San Diego, where he helps to train endocrinology fellows. He is a past president of the California chapter and former board member of the American Association of Clinical Endocrinologists. 
He has served as Principal Investigator on more than 200 phase 1 to 4 clinical trials testing new medications and technology for diabetes including sensors, delivery devices, and the "artificial pancreas". He has a particular interest in human factors testing and real-world trials, with the goal of improving adherence, persistence and the overall effectiveness of therapies for people with diabetes.

Read more arrow_downward Hide arrow_upward

Research Support: Abbott, Capillary Biomedical , Dexcom, Diasome, Eli Lilly, Kowa, Lexicon, Medtronic, Medtrum, Novo Nordisk, REMD, Sanofi, Senseonics, Viacyte, vTv Therapeutics, Zealand Pharma

Consulting Honoraria:  Abbott, Lifescan, Novo, Sanofi

Speaking Honoraria:  Medtronic, Sanofi